Humanized bispecific anti-CD20×CD3 monoclonal antibody that redirects T-cell cytotoxicity against CD20-positive B cells; given with step-up dosing to mitigate cytokine release syndrome.
Humanized bispecific antibody (2:1 CD20:CD3) that bridges CD20-positive B cells and CD3-positive T cells, activating T cells to form an immune synapse and kill target B cells via perforin/granzyme-mediated cytotoxicity; step-up dosing is used to mitigate cytokine release syndrome.
NO
INDIRECT
Bispecific T‑cell engager: binds CD3 on T cells and CD20 on B cells to form an immune synapse; activated T cells kill CD20+ B cells via perforin/granzyme. CD3+ T cells are not targeted for killing.
Anti–Trop-2 antibody–drug conjugate delivering SN-38 (topoisomerase I inhibitor).
Humanized anti-Trop-2 monoclonal antibody linked to SN-38; binds Trop-2 on tumor cells, is internalized, and releases SN-38, a topoisomerase I inhibitor that stabilizes topo I-DNA complexes to cause DNA breaks, inhibit replication, and induce apoptosis.
NO
INDIRECT
The ADC binds Trop-2 on tumor cells, is internalized, and releases SN-38, which inhibits topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I expression alone does not direct targeting or selective killing.
Type II, glycoengineered anti-CD20 monoclonal antibody that depletes B cells via enhanced ADCC, CDC, and direct cell death; used early to reduce CRS risk.
Glycoengineered humanized IgG1 type II anti-CD20 monoclonal antibody that binds CD20 on B cells; afucosylated Fc increases affinity for Fc gamma RIIIa (CD16a) to enhance antibody-dependent cellular cytotoxicity (ADCC); also triggers direct, caspase-independent cell death and can activate complement-dependent cytotoxicity (CDC), depleting CD20-positive malignant B cells.
YES
DIRECT
Binds CD20 on B cells and kills via enhanced ADCC through Fc gamma RIIIa engagement, complement-dependent cytotoxicity (CDC), and direct caspase-independent cell death.
Type II, glycoengineered anti-CD20 monoclonal antibody that depletes B cells via enhanced ADCC, CDC, and direct cell death; used early to reduce CRS risk.
Glycoengineered humanized IgG1 type II anti-CD20 monoclonal antibody that binds CD20 on B cells; afucosylated Fc increases affinity for Fc gamma RIIIa (CD16a) to enhance antibody-dependent cellular cytotoxicity (ADCC); also triggers direct, caspase-independent cell death and can activate complement-dependent cytotoxicity (CDC), depleting CD20-positive malignant B cells.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages CD16a on NK cells to mediate ADCC (and can trigger CDC/direct death) against CD20+ B cells. CD16a-expressing cells are effector cells, not killed by the drug.
Type I chimeric anti-CD20 monoclonal antibody that depletes B cells via ADCC, CDC, and apoptosis.
Type I chimeric anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and induces B‑cell depletion primarily via Fc‑mediated ADCC and complement‑dependent cytotoxicity, with additional direct apoptosis.
YES
DIRECT
Anti‑CD20 IgG1 binds CD20 on B cells and triggers Fc‑mediated ADCC (NK cells/macrophages), complement‑dependent lysis (CDC), and some direct apoptosis via CD20 crosslinking.